Human umbilical vein endothelial cell proliferation (HUVEC proliferation)

Human umbilical vein endothelial cell (HUVEC) proliferation is a fundamental biological process involving the replication of endothelial cells, which line the interior surface of blood vessels. It is not a single molecular target but rather a complex cellular response regulated by various growth factors, most notably Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth Factor (FGF) (PubMed: 15134354). In oncology, HUVEC proliferation assays are widely used to screen for anti-angiogenic drugs that inhibit tumor vascularization, such as Bevacizumab or Sunitinib (NIH: PMC2822454). In cardiovascular research, this process is studied to understand re-endothelialization after vascular injury or stent placement. Because it encompasses an entire physiological pathway rather than a specific protein, it is considered a phenotypic readout or biological process in pharmacological contexts. Consequently, drugs "targeting" HUVEC proliferation actually interact with specific upstream receptors or intracellular signaling molecules like VEGFR2 or MAPK.

Other names

Endothelial cell proliferationHUVEC growthAngiogenesis assay readout

Inhibition of pro-angiogenic signaling pathways, primarily the VEGF/VEGFR axis, which triggers the intracellular cascades necessary for endothelial cell cycle progression and division (PubMed: 15134354).